In today’s session Illumina, Inc. (ILMN) registered an unusually high (251) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious ILMN increase. With 251 contracts traded and 8014 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: ILMN170120C00170000 closed last at: $0.8 or 27.3% down. About 179,393 shares traded hands. Illumina, Inc. (NASDAQ:ILMN) has declined 24.72% since April 18, 2016 and is downtrending. It has underperformed by 29.15% the S&P500.
Illumina, Inc. (NASDAQ:ILMN) Ratings Coverage
Out of 23 analysts covering Illumina Inc (NASDAQ:ILMN), 7 rate it a “Buy”, 2 “Sell”, while 14 “Hold”. This means 30% are positive. Illumina Inc has been the topic of 47 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The rating was maintained by Stifel Nicolaus on Tuesday, October 6 with “Buy”. Cowen & Co maintained Illumina, Inc. (NASDAQ:ILMN) rating on Tuesday, April 19. Cowen & Co has “Outperform” rating and $180 price target. The stock of Illumina, Inc. (NASDAQ:ILMN) earned “Neutral” rating by CItigroup on Tuesday, October 11. Citigroup downgraded the shares of ILMN in a report on Tuesday, October 11 to “Neutral” rating. The firm has “Outperform” rating by Cowen & Co given on Friday, October 2. The firm earned “Hold” rating on Thursday, January 7 by Deutsche Bank. The firm has “Equal-Weight” rating given on Tuesday, October 13 by Barclays Capital. On Monday, December 21 the stock rating was maintained by Stifel Nicolaus with “Buy”. As per Thursday, November 10, the company rating was reinitiated by Leerink Swann. The firm has “Market Perform” rating given on Tuesday, April 19 by Leerink Swann.
According to Zacks Investment Research, “Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company’s tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.”
Insitutional Activity: The institutional sentiment decreased to 1.07 in Q2 2016. Its down 0.03, from 1.1 in 2016Q1. The ratio worsened, as 66 funds sold all Illumina, Inc. shares owned while 150 reduced positions. 46 funds bought stakes while 191 increased positions. They now own 137.98 million shares or 3.82% less from 143.46 million shares in 2016Q1.
Motco holds 0.01% or 475 shares in its portfolio. Federated Invsts Pa last reported 0% of its portfolio in the stock. American Century has 143,817 shares for 0.02% of their US portfolio. Forte Cap Ltd Adv has invested 0.12% of its portfolio in Illumina, Inc. (NASDAQ:ILMN). Cypress Asset Inc Tx reported 1,960 shares or 0.05% of all its holdings. Bancshares Of Montreal Can reported 68,370 shares or 0.01% of all its holdings. Washington Tru Comml Bank last reported 0% of its portfolio in the stock. Atlanta Grp Inc accumulated 0.29% or 9,171 shares. Canada Pension Plan Board holds 20,622 shares or 0.01% of its portfolio. Halsey Associates Ct reported 12,510 shares or 0.39% of all its holdings. Ameriprise Fin Inc accumulated 3.32M shares or 0.27% of the stock. Moreover, Alpine Woods Cap Invsts Ltd Liability has 0.27% invested in Illumina, Inc. (NASDAQ:ILMN) for 32,500 shares. Natixis Asset Management accumulated 0.65% or 42,426 shares. Clearbridge Investments Limited accumulated 205 shares or 0% of the stock. Blackrock Institutional Trust Com Na has 0.09% invested in the company for 3.84 million shares.
Insider Transactions: Since May 25, 2016, the stock had 0 buys, and 26 insider sales for $16.21 million net activity. On Thursday, September 15 the insider Stapley Marc sold $219,543. BOWMAN A BLAINE sold $735,705 worth of stock or 5,000 shares. Shares for $1.34M were sold by Dadswell Charles on Wednesday, July 27. On Monday, July 18 the insider EPSTEIN ROBERT S sold $180,000. $1.50M worth of Illumina, Inc. (NASDAQ:ILMN) was sold by FLATLEY JAY T. 600 shares with value of $110,613 were sold by BRADBURY DANIEL on Friday, October 7. HENRY CHRISTIAN O sold $295,242 worth of Illumina, Inc. (NASDAQ:ILMN) on Wednesday, June 15.
Illumina, Inc. offers sequencing and array solutions for genetic analysis. The company has a market cap of $19.04 billion. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. It has a 44.51 P/E ratio. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
ILMN Company Profile
Illumina, Inc. (Illumina), incorporated on May 16, 2000, offers sequencing and array solutions for genetic analysis. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina provides sample-to-answer solutions to its clients in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. Illumina provides reproductive-health solutions, including preimplantation genetic screening and diagnosis (PGS and PGD), noninvasive prenatal testing (NIPT), and neonatal and genetic health testing. The Company’s BaseSpace platform, which can be hosted onsite or in the cloud, integrates directly with its sequencing instruments, facilitates data sharing, provides data-storage solutions and streamlines analysis. It has activities in the United States, Europe, Asia-Pacific and other markets.
More notable recent Illumina, Inc. (NASDAQ:ILMN) news were published by: Fool.com which released: “Is Illumina Inc. a Buffett Stock?” on November 08, 2016, also Fool.com with their article: “Illumina Inc. Is Floundering: Here’s What Management Had to Say” published on November 04, 2016, Fool.com published: “Illumina, Inc. in 3 Charts” on October 26, 2016. More interesting news about Illumina, Inc. (NASDAQ:ILMN) were released by: Fool.com and their article: “Illumina Inc. Q3 Weighed Down by Sluggish High-Throughput System Sales” published on November 02, 2016 as well as Businesswire.com‘s news article titled: “Illumina and Mayo Clinic Form Bioinformatics Relationship to Advance Genetic …” with publication date: November 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.